Granted to a 2-year-old child, Kosovo benefits most expensive drug in the world

A child under the age of two in Kosovo has taken among the most expensive medicines in the world, known as “Zolgensma”. This genetic therapy has been applied to treat muscle atrophy disease.

This is the first time this genetic therapy has been given to Kosovo, which is worth about two million and $150,000.

The chief of the Institute of Neurology at the Paddy Department, Naim Zeka, has shown the procedures they have followed to gain free therapy from the company “Novartis”.

According to him, this drug is expected to revolutionize in its treatment.

He said that the disease is rare and deadly.

On March 7th of this year, we have applied genetic therapy for muscle atrophy disease. It is a deadly disease, which until a few years ago has been deemed to die these children. Fortunately four years ago, some five years ago started with treatment therapy. And we've had the fate that we've started with genetic therapy, which is one of the most modern therapies, therapy that's just expected to revolutionize the treatment of this disease, is about the onasemnogene-abbeparvovec bar, or otherwise known as "Zolgensma," is a preparat that changes the structure of the gene that causes the disease, and luckily has started to be used in different parts of the world <x1, He claims Zeka.

The child has received therapy for two weeks without filling in two years. It means within those criteria for using therapy. It's the most expensive therapy in the world today. A dose for a child costs about $2 million and $150,000, a cost that is unaffordable not only to our country but also to other countries. We have had the destiny of being one of the applicant states and why many countries like Bosnia, Montenegro, Albania, Macedonia have yet to apply any dose. We've had the luck of being in the group of states that we've started applying for this therapy and we're very happy that the therapy has gone successfully”, He says it.

The Pharisee treats eight children with muscle atrophy.

Two cycles of training have been developed for the application of the most expensive drug in the world through the company's central staff “Novartis”.